

## Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **December 1, 2024** update to the *Alberta Drug Benefit List (ADBL)* has been posted online at [ab.bluecross.ca/dbl/publications.php](http://ab.bluecross.ca/dbl/publications.php).

Please refer to the **December 1, 2024** update for complete listing of products available by special authorization, restricted benefit/special authorization, products with changes for coverage, added products, least cost alternative price changes, products with a price change, discontinued listings and delisted products.

Please note that the online *interactive Drug Benefit List (iDBL)* at [ab.bluecross.ca/dbl/idbl\\_main1.php](http://ab.bluecross.ca/dbl/idbl_main1.php) is a near real-time application, and as such, contains the most up-to-date information.

## Removal of temporary benefit from the ADBL

Due to the shortages of pms-Oxycodone 5 mg Tablet (DIN 02319977) and Supeudol 5 mg Tablet (DIN 00789739), manufactured by Sandoz Canada Inc., **Oxy-IR 5 mg Tablet (DIN 02231934)**, manufactured by Purdue Pharma, was added as a temporary benefit to the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross® has confirmed that the shortage for pms-Oxycodone 5 mg Tablet (DIN 02319977) has been resolved.

Due to the short-term nature of this shortage, **Oxy-IR 5 mg Tablet (DIN 02231934)** will no longer be considered as a temporary benefit in the *ADBL* **after November 13, 2024**. The above grouping was removed from the Critical Supply Product List on **November 13, 2024**.

## Product supply shortages addressed for ADBL

Alberta Blue Cross® has confirmed that the shortage for Rabeprazole 10 mg Enteric-Coated Tablet (DIN 02356511), manufactured by Sanis Health Inc., has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **December 9, 2024**. The following grouping was removed from the Critical Supply Product List on **November 8, 2024**.

### RABEPRAZOLE SODIUM

#### 10 MG ENTERIC-COATED TABLET

00002415283	JAMP RABEPRAZOLE	JPC	\$0.0669
00002385449	RABEPRAZOLE	SIV	\$0.0669
00002356511	RABEPRAZOLE EC	SNS	\$0.0669
00002314177	SANDOZ RABEPRAZOLE	SDZ	\$0.0669
00002243796	PARIET	JAI	\$1.0890

*continued next page*

## PHARMACY BENEFACT

continued from previous page

Alberta Blue Cross® has confirmed that the shortage for GD-Diclofenac/Misoprostol 75 mg/200 mcg Enteric-Coated Tablet (DIN 02341697) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **December 13, 2024**. The following grouping was removed from the Critical Supply Product List on **November 13, 2024**.

### DICLOFENAC SODIUM / MISOPROSTOL

#### 75 MG/200 MCG ENTERIC-COATED TABLET

00002341697	GD-DICLOFENAC / MISOPROSTOL	GMD	\$0.4286
00002413477	PMS-DICLOFENAC-MISOPROSTOL	PMS	\$0.4286
00002229837	ARTHROTEC-75	PFI	\$1.0138

Alberta Blue Cross® has confirmed that the shortages for Auro-Olmesartan 20 mg Tablet (DIN 02443864), Jamp-Olmesartan 20 mg Tablet (DIN 02461641), and Olmesartan 20 mg Tablet (DIN 02481057), manufactured by Sanis Health Inc., have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **December 16, 2024**. The following grouping was removed from the Critical Supply Product List on **November 14, 2024**.

### OLMESARTAN MEDOXOMIL

#### 20 MG TABLET

00002456311	ACH-OLMESARTAN	AHI	\$0.3019
00002442191	ACT OLMESARTAN	TEV	\$0.3019
00002453452	APO-OLMESARTAN	APX	\$0.3019
00002443864	AURO-OLMESARTAN	AUR	\$0.3019
00002469812	GLN-OLMESARTAN	GLM	\$0.3019
00002461641	JAMP-OLMESARTAN	JPC	\$0.3019
00002499258	NRA-OLMESARTAN	NRA	\$0.3019
00002481057	OLMESARTAN	SNS	\$0.3019
00002461307	PMS-OLMESARTAN	PMS	\$0.3019
00002443414	SANDOZ OLMESARTAN	SDZ	\$0.3019
00002318660	OLMETEC	ORC	\$1.1607

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://ab.bluecross.ca/providers/pharmacy-home.php)

